London · Delayed Price · Currency is GBP · Price in GBX ValiRx Company Description
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.
The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells.
The company also develops and commercializes oncology assets in the veterinary market. It has an agreement with University of Dundee.
ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
| Country | United Kingdom |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Mark Eccleston |
Contact Details
Address: Stonebridge House England, CM22 7BD United Kingdom | |
| Website | valirx.com |
Stock Details
| Ticker Symbol | VAL |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BLH13C52 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Eccleston | Chief Executive Officer |
| James Desler | Chief Financial Officer |
| Kumar Nawani | Chief Operating Officer |